Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies

Zhao, Xinnan; Yang, Pingting

doi:10.1016/j.jneuroim.2021.577648

Cited by 6 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Deanxit (flupentixol and melitracen tablets), Prozac (fluoxetine), and traditional Chinese medicine were commonly used as drug therapies [ 13 ]. Drugs such as paeoniflorin have been shown to alleviate depressive behavior in SLE mice [ 14 ], and hydroxychloroquine also indicated an ability to alleviate anti-RibP-induced neurotoxicity [ 15 ]. However, drug treatment can have side effects and will cross-react with the multi-organ immunity to SLE.…”

Section: Discussionmentioning

confidence: 99%

Anti-ribosomal P protein antibodies and insomnia correlate with depression and anxiety in patients suffering from systemic lupus erythematosus

Leng¹,

Su²,

Wang³

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anti-ribosomal P protein antibodies and insomnia correlate with depression and anxiety in patients suffering from systemic lupus erythematosus

Leng¹,

Su²,

Wang³

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Petri et al examined HCQ blood levels in a longitudinal SLE cohort to prove that low HCQ blood levels were associated with thrombotic events in SLE ( 65 ). It was indicated that HCQ could block intracellular calcium signaling in macrophages and lymphocytes ( 66 , 67 ) and attenuate anti-ribosomal P-induced neurotoxicity by preventing intracellular calcium signals and apoptosis in neurons ( 68 ). HCQ could also prevent β2-glycoprotein I complex from binding to phospholipid bilayers and cells and protect the annexin A5 anticoagulant shield from being destroyed by antiphospholipid antibodies, which was considered to decrease the risk of thrombosis in APS and SLE ( 69 , 70 ).…”

Section: Discussionmentioning

confidence: 99%

Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study

Zai-kang

Guan

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

ObjectivesIschemic cerebrovascular disease (ICVD) is one of the most common and severe complications in systemic lupus erythematosus (SLE). We aim to explore the risk factors for ICVD in SLE and to assess their associated clinical characteristics.MethodsIn this study, 44 lupus patients with ICVD (ICVD-SLE) and 80 age- and sex-matched lupus patients without ICVD (non-ICVD-SLE) who were hospitalized in our center between 2014 and 2021 were enrolled. A comprehensive set of clinical and socio-demographic data was recorded. In the ICVD-SLE group, the modified Rankin score (mRS) at 90 days after the occurrence of ICVD, the brain MRI, and arterial ultrasonography findings were collected. Group comparisons were made with continuous variables using an independent t-test or the Mann–Whitney test, and with categorical variables using the chi-square test or Fisher exact test. Multivariate logistic regression analysis was performed to identify the risk factors for ICVD in SLE. Patients with ICVD-SLE were divided into three subgroups according to the gradations of intracranial arterial stenosis (ICAS). The subgroup comparisons were performed by one-way ANOVA test or Kruskal–Wallis test.ResultsOf the 44 patients with ICVD, 45% had a large-vessel ischemic stroke, 50% had a symptomatic lacunar stroke, and 9% had a transient ischemic attack. 2 (4.5%) had both large-vessel ischemic stroke and symptomatic lacunar stroke. Multivariate logistic regression analysis showed that cutaneous vasculitis (OR=7.36, 95% CI=2.11–25.65), anticardiolipin antibody (aCL) (OR=4.38, 95% CI=1.435–13.350), and lupus anticoagulant (LA) (OR=7.543,95% CI=1.789–31.808) were the risk factors, and hydroxychloroquine (HCQ) therapy (OR=0.198, 95% CI=0.078–0.502) was the protective factor, after controlling for confounders. During the analysis of the subgroups, no significant difference was observed between the patients in the group without internal carotid arterial occlusion (ICAS) and those with severe ICAS except for diagnostic delay. However, patients in the moderate ICAS group were older when SLE occurred (P<0.01), had a longer diagnostic delay (P<0.01), a lower percentage of hypocomplementemia (P=0.05) and steroids and HCQ therapy (P=0.01, P=0.05, respectively), a trend toward lower mRS score, but a higher incidence of carotid atherosclerotic plaque (P<0.01), when compared with the other two subgroups.ConclusionCutaneous vasculitis and antiphospholipid antibodies (aPLs) are associated with an increased risk of ICVD, while HCQ therapy may provide protection against ICVD in SLE. The ICVD in younger lupus patients is associated with complement-mediated inflammation and poorer outcome, and require immunosuppressive therapy, whereas the ICVD in elderly patients are characterized by moderate ICAS and carotid atherosclerotic plaques.

show abstract

Prediction model for developing neuropsychiatric systemic lupus erythematosus in lupus patients

Feng,

Su,

Liu

et al. 2024

Clin Rheumatol

View full text Add to dashboard Cite

Hydroxychloroquine alleviates the neurotoxicity induced by anti-ribosomal P antibodies

Cited by 6 publications

References 35 publications

Anti-ribosomal P protein antibodies and insomnia correlate with depression and anxiety in patients suffering from systemic lupus erythematosus

Anti-ribosomal P protein antibodies and insomnia correlate with depression and anxiety in patients suffering from systemic lupus erythematosus

Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study

Prediction model for developing neuropsychiatric systemic lupus erythematosus in lupus patients

Contact Info

Product

Resources

About